Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 17;14:5029–5041. doi: 10.2147/DDDT.S266470

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Chiu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Recurrent HCCs in a 70-year old man with HBV cirrhosis of liver and HCC in the both lobes of the liver received TACE before. (A) After the chemoembolization of splenic artery with drug-eluting beads, the nonenhanced CBCT after TACE showed contrast retention in the spleen (arrows), indicative of nontarget embolization. Also note contrast retention in the HCC located in the left lateral segment of liver (dotted line). (B) The follow-up CT one month after TACE showed wedge-shaped poor-enhancing area (arrows) in the spleen on portal venous phase, compatible with splenic infarction caused by nontarget embolization during TACE.